Last reviewed · How we verify
NCT03168100
2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
Phase 2 trial testing Elotuzumab in Multiple Myeloma. Withdrawn.
24 January 2019
Quick facts
| Lead sponsor | University of Arkansas |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 October 2017 |
| Primary completion | 24 January 2019 |
| Estimated completion | 24 January 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Elotuzumab (elotuzumab) — full drug profile →
- Lenalidomide — full drug profile →
- Dexamethasone (dexamethasone) — full drug profile →
- Bortezomib (bortezomib) — full drug profile →
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
University of Arkansas
Who can join
Adults 18 to 75, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Total Therapy treatment regimens developed at the Myeloma Institute have demonstrated great improvement in treatment outcomes for multiple myeloma patients. However, some patients still relapse early during maintenance treatment meaning that better options are still needed. This study will evaluate a treatment regimen that alternates two different 3-drug regimens every eight weeks for patients that have previously completed autologous stem cell transplant. The two regimens are bortezomib, lenalidomide, and dexamethasone (VRD) which will be alternated with Elotuzumab, lenalidomide, and dexamethasone (Elo RD). Effectiveness will be measured by the depth of response (i.e., whether or not minimal residual disease (MRD) negative status is achieved). The rate of MRD negativity from this study will be compared to historical control data from the Total Therapy 4 trial which used continuous VRD maintenance therapy after stem cell transplant(s).
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update.
Abramson HN. · · 2018 · cited 42× · PMID 30544512 · DOI 10.3390/ijms19123924 -
Myeloid checkpoints for cancer immunotherapy.
Qian Y, Yang T, Liang H, Deng M. · · 2022 · cited 22× · PMID 36398127 · DOI 10.21147/j.issn.1000-9604.2022.05.07 -
Treatment Strategy for Ultra-High-Risk Multiple Myelomas with Chromosomal Aberrations Considering Minimal Residual Disease Status and Bone Marrow Microenvironment.
Suzuki K, Yano S. · · 2023 · cited 1× · PMID 37173885 · DOI 10.3390/cancers15092418
Verify or expand the search:
- PubMed search for NCT03168100
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Elotuzumab
Trials testing the same drug.
- NCT06785415 — Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma · Phase 1, PHASE2 · recruiting
- NCT06518551 — Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM · Phase 1, PHASE2 · recruiting
- NCT06232707 — A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapse · Phase 3 · withdrawn
- NCT06152575 — MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Ha · Phase 3 · recruiting
- NCT06208150 — A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamet · Phase 3 · recruiting
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other University of Arkansas trials
Trials by the same sponsor.
- NCT07029776 — MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma · Phase 2 · not yet recruiting
- NCT07341399 — Essential Amino Acid Supplementation in Adult Spinal Deformity Patients · NA · not yet recruiting
- NCT07071766 — Improving Outcomes for Early Postpartum Mothers in Outpatient MOUD Treatment · NA · recruiting
- NCT05823727 — Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing Afte · NA · recruiting
- NCT06604065 — Essential Amino Acids and Parkinsons Disease · Phase 1 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03168100 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Arkansas
- Last refreshed: 28 January 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03168100.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing